Company intelligence / Profile preview

Vetex Medical

GALWAY, Irelandx.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company developed the ReVene Thrombectomy Catheter for single-session mechanical removal of venous clots. Clinical feasibility data from a trial with a 12-month follow-up on nineteen patients showed all primary endpoints were met with no safety issues. The device received FDA clearance in December 2020 and CE Mark in May 2021. It was designed to minimize or eliminate the need for thrombolytic drugs and ICU care by efficiently removing large-volume clots without capital equipment.

Therapeutic areas: Cardiovascular
Modalities: Device (specifically mechanical thrombectomy catheter)
Industry: Therapeutic Medical Devices

Partnerships

SurModics (acquirer)European Commission as investor/supporter

Beyond the preview

Go deeper on Vetex Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vetex Medical.

Explore the full profile